[Objective] To investigate and summarize the clinicopathological features, diagnosis, treatment and prognosis of adrenocortical carcinoma with rhabdoid features. [Methods] The clinical diagnosis and treatment of a case of adrenocortical carcinoma with rhabdoid features admitled to Department of Urology, Weifang People's Hospital were reported.The clinical manifestations, pathological features, diagnosis and prognosis of the disease were analyzed in combination with relevant literature. [Results] A 34-year-old male patient was admitted due to scrotal distension and pain that had persisted for 6 months.Imaging examination showed a huge soft tissue tumor in the left adrenal region of the retroperitoneum with compression displacement of the left kidney, leading to obstruction of venous return in the left spermatic vein, which in turn caused varicose veins.The levels of serum renin, angiotensin, aldosterone, cortisol, and catecholamine were within normal ranges.Surgical resection of the tumor was performed, and postoperative pathological examination revealed that the tumor tissue was predominantly composed of rhabdoid cells, exhibiting positive immunohistochemical staining for INI 1, Syn, Calretinin and Vimentin.Genetic testing did not identify any deletion of SMARCB1 and SMARCA4 mutations.Therefore, the diagnosis was adrenocortical carcinoma with rhabdoid features.At the current 20-month follow-up, no recurrence or metastasis was observed.A review of the literature found that only 7 cases of this disease had been reported. [Conclusion] Adrenocortical carcinoma with rhabdoid features is a rare disease, and a definitive diagnosis is dependent upon pathological examination.Surgical resection remains the primary treatment.Long-term follow-up is essential, and further research is needed to evaluate the impact of adjuvant therapy.

Objective:To explore the anti-reflux effect of transverse fan-shaped groin formed (TFGF) when the residual stomach is large (the small curvature ≥10 cm).Methods:Twenty-four patients with residual curvature ≥10 cm after PG were treated with TFGF continuously from Nov 2020 to Dec 2023 in this study. The cohort included 20 patients with Siewert type Ⅱ adenocarcinoma of the esophagogastric junction and 4 patients with achalasia of cardia. Reflux disease questionnaire score gastroesophageal reflux disease questionnaire score and gastroscopy Los Angeles score were used to evaluate the anti-reflux effect and postoperative nutritional parameters (hemoglobin, protein and body weight).Results:The reconstructive operation time of adenocarcinoma of the esophago-gastric junction and achalasia of cardia was (20.0±5.1) min and (18.3±4.7) min, respectively. reflux disease questionnaire, gastro-esophageal reflux disease questionnaire and gastroscopy indicated GERD in 3 patients and 8% in 2 patients at 24 months. At follow-up, one patient transitioned from grade B to grade C based on the Los Angeles score at 12 months; 24 months after surgery, one patient's gastroesophageal reflux symptoms resolved and the Los Angeles rating was downgraded from B to A. Nutritional indicators (hemoglobin, protein and body weight levels) all showed a downward trend at 6 months and an upward trend at 24 months.Conclusion:TFGF has the advantages of simple operation, and effective prevention of postoperative gastroesophageal reflux for patients with lesser residual curvature ≥10 cm after PG.

The relationship between macrophages and acute ischemic stroke is currently a research hotspot.Previous studies have shown that macrophages in the central nervous system,vascular wall,and circulatory system can affect acute ischemic stroke through different mechanisms such as exacerbating inflammatory responses,phagocytosis,or inducing ferroptosis of vascular endothelial cells.In addition,during the occurrence of acute ischemic stroke,macrophages in the vascular wall and circulating system play a significant role through exosomes.This article reviewed the pathogenic mechanisms of macrophages in acute ischemic stroke,with the aim of providing a reference for in-depth research on the relationship between macrophages and acute ischemic stroke and the development of precise treatment plans.

Trophoblast cell surface antigen 2 (Trop2) is a transmembrane glycoprotein. It promotes development and coordinates intracellular calcium signal transduction in healthy tissues, but is overexpressed in a variety of solid malignant tumors (such as gastrointestinal tumors, ovarian cancer, prostate cancer, and breast cancer). Moreover, it is closely associated with poor tumor prognosis and metastasis risk. As a powerful tool, molecular imaging technology can directly characterize and quantify the molecular metabolic changes after the combination of probes and targets through imaging technology at the in vivo level. It has become a key technology for Trop2 research and plays an important role in specific diagnosis, tumor staging, and therapeutic effect monitoring. A variety of Trop2-targeted molecular probes based on monoclonal antibodies, antibody-drug conjugates, and antibody fragments have been used in preclinical and clinical studies of various solid tumors. This article reviews the latest progress of Trop2-related research in the field of tumor molecular imaging technology.

The relationship between macrophages and acute ischemic stroke is currently a research hotspot.Previous studies have shown that macrophages in the central nervous system,vascular wall,and circulatory system can affect acute ischemic stroke through different mechanisms such as exacerbating inflammatory responses,phagocytosis,or inducing ferroptosis of vascular endothelial cells.In addition,during the occurrence of acute ischemic stroke,macrophages in the vascular wall and circulating system play a significant role through exosomes.This article reviewed the pathogenic mechanisms of macrophages in acute ischemic stroke,with the aim of providing a reference for in-depth research on the relationship between macrophages and acute ischemic stroke and the development of precise treatment plans.

Multiple myeloma (MM) is a malignant blood disease, but there have been significant improvements in the prognosis due to advancements in quantitative assessment, immunotherapy, and targeted therapy in recent years. The quantitative assessment of MM bone marrow infiltration and prognosis prediction is influenced by imaging and artificial intelligence (AI) quantitative parameters. At present, the primary imaging methods include computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET). These methods are now crucial for diagnosing MM and evaluating myeloma cell infiltration, extramedullary disease, treatment effectiveness, and prognosis. In addition, the utilization of AI, especially in combination with machine learning and radiomics, has shown great potential in diagnosing and distinguishing MM from solubility transfer. This review discusses the advancements in imaging methods, including CT, MRI, and PET, as well as AI for quantitatively assessing MM. We have summarized the key concepts, advantages, limitations, and diagnostic performance of each technology. Finally, we discussed the challenges related to clinical implementation and presented our views on advancing this field, with the aim of providing guidance for clinical research.

Multiple myeloma (MM) is a malignant blood disease, but there have been significant improvements in the prognosis due to advancements in quantitative assessment, immunotherapy, and targeted therapy in recent years. The quantitative assessment of MM bone marrow infiltration and prognosis prediction is influenced by imaging and artificial intelligence (AI) quantitative parameters. At present, the primary imaging methods include computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET). These methods are now crucial for diagnosing MM and evaluating myeloma cell infiltration, extramedullary disease, treatment effectiveness, and prognosis. In addition, the utilization of AI, especially in combination with machine learning and radiomics, has shown great potential in diagnosing and distinguishing MM from solubility transfer. This review discusses the advancements in imaging methods, including CT, MRI, and PET, as well as AI for quantitatively assessing MM. We have summarized the key concepts, advantages, limitations, and diagnostic performance of each technology. Finally, we discussed the challenges related to clinical implementation and presented our views on advancing this field, with the aim of providing guidance for clinical research.

Trophoblast cell surface antigen 2 (Trop2) is a transmembrane glycoprotein. It promotes development and coordinates intracellular calcium signal transduction in healthy tissues, but is overexpressed in a variety of solid malignant tumors (such as gastrointestinal tumors, ovarian cancer, prostate cancer, and breast cancer). Moreover, it is closely associated with poor tumor prognosis and metastasis risk. As a powerful tool, molecular imaging technology can directly characterize and quantify the molecular metabolic changes after the combination of probes and targets through imaging technology at the in vivo level. It has become a key technology for Trop2 research and plays an important role in specific diagnosis, tumor staging, and therapeutic effect monitoring. A variety of Trop2-targeted molecular probes based on monoclonal antibodies, antibody-drug conjugates, and antibody fragments have been used in preclinical and clinical studies of various solid tumors. This article reviews the latest progress of Trop2-related research in the field of tumor molecular imaging technology.

Objective:To explore the anti-reflux effect of transverse fan-shaped groin formed (TFGF) when the residual stomach is large (the small curvature ≥10 cm).Methods:Twenty-four patients with residual curvature ≥10 cm after PG were treated with TFGF continuously from Nov 2020 to Dec 2023 in this study. The cohort included 20 patients with Siewert type Ⅱ adenocarcinoma of the esophagogastric junction and 4 patients with achalasia of cardia. Reflux disease questionnaire score gastroesophageal reflux disease questionnaire score and gastroscopy Los Angeles score were used to evaluate the anti-reflux effect and postoperative nutritional parameters (hemoglobin, protein and body weight).Results:The reconstructive operation time of adenocarcinoma of the esophago-gastric junction and achalasia of cardia was (20.0±5.1) min and (18.3±4.7) min, respectively. reflux disease questionnaire, gastro-esophageal reflux disease questionnaire and gastroscopy indicated GERD in 3 patients and 8% in 2 patients at 24 months. At follow-up, one patient transitioned from grade B to grade C based on the Los Angeles score at 12 months; 24 months after surgery, one patient's gastroesophageal reflux symptoms resolved and the Los Angeles rating was downgraded from B to A. Nutritional indicators (hemoglobin, protein and body weight levels) all showed a downward trend at 6 months and an upward trend at 24 months.Conclusion:TFGF has the advantages of simple operation, and effective prevention of postoperative gastroesophageal reflux for patients with lesser residual curvature ≥10 cm after PG.

Recent clinical studies have shown that mutation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene in cancer cells may be associated with immunosuppressive tumor microenvironment (TME) and poor response to immune checkpoint blockade (ICB) therapy. Therefore, efficiently restoring PTEN gene expression in cancer cells is critical to improving the responding rate to ICB therapy. Here, we screened an adeno-associated virus (AAV) capsid for efficient PTEN gene delivery into B16F10 tumor cells. We demonstrated that intratumorally injected AAV6-PTEN successfully restored the tumor cell PTEN gene expression and effectively inhibited tumor progression by inducing tumor cell immunogenic cell death (ICD) and increasing immune cell infiltration. Moreover, we developed an anti-PD-1 loaded phospholipid-based phase separation gel (PPSG), which formed an in situ depot and sustainably release anti-PD-1 drugs within 42 days in vivo. In order to effectively inhibit the recurrence of melanoma, we further applied a triple therapy based on AAV6-PTEN, PPSG^@anti-PD-1 and CpG, and showed that this triple therapy strategy enhanced the synergistic antitumor immune effect and also induced robust immune memory, which completely rejected tumor recurrence. We anticipate that this triple therapy could be used as a new tumor combination therapy with stronger immune activation capacity and tumor inhibition efficacy.